Last reviewed · How we verify
Genetic and immunology tests
At a glance
| Generic name | Genetic and immunology tests |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
- Fatigue
- Neutrophil count decreased
- White blood cell decreased
- Platelet count decreased
- Hypertension
- Anemia
- Peripheral sensory neuropathy
- Lymphocyte count decreased
- Diarrhea
- Fever
- Aspartate aminotransferase increased
- Arthralgia
Key clinical trials
- Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV) (NA)
- Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (PHASE1)
- Pre-malignant States to Hematologic Malignancies in Firefighters
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD) (NA)
- Cell Marker Predictors in Barrett's Esophagus
- Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors (PHASE2)
- Comprehensive Assessment of First Trimester Pregnancy Loss
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Genetic and immunology tests CI brief — competitive landscape report
- Genetic and immunology tests updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI